CARLOTTA01Recruiting

New CAR-T cell therapy for previously treated diffuse large B-cell lymphoma (DLBCL) or multiple myeloma

Gender
Women and men
Age
18 years and older
Trial type
Interventional
Line of therapy
Relapsed / refractory
Phase
Phase I

What is this trial about?

Diffuse large B-cell (DLBCL) and (MM) are malignant diseases of the that may recur (relapse) or become unresponsive to treatment () despite . In this situation, a new form of therapy using so-called - could be an effective treatment option. The goal of the CARLOTTA01 study is to investigate the safety and maximum tolerated dose of a new CAR-T cell drug (designation: MDC-CAR-BCMA001). Patients aged 18 years and older with refractory or relapsed or MM are eligible to participate in the study. There must be no involvement of the central nervous system (CNS).

Detailed description

Diffuse large B-cell lymphoma (DLBCL) is a form of that affects —a subgroup of white blood cells that play an important role in the immune system. DLBCL is often characterized by rapid enlargement of the lymph nodes, frequently accompanied by involvement of other organs outside the lymph nodes. Typical symptoms include fever, night sweats, and unintentional weight loss. Multiple myeloma (MM) is a malignant disease of the in the bone marrow—these, too, belong to the group of B lymphocytes. Since the myeloma spreads in the bone marrow, those affected often complain of bone pain. The exact causes of both diseases have not yet been fully elucidated. However, it is believed that genetic and environmental factors play a role. While a cure can often be achieved in DLBCL through intensive immunochemotherapy, this is only very rarely possible in MM. Myeloma, however, can generally be treated effectively, allowing the disease to remain inactive for a long time. Nevertheless, both DLBCL and MM can recur over time or develop resistance to previous therapies. Most recently, a new form of therapy—treatment with CAR-T cells—has been tested for both diseases. Several CAR-T-cell therapies have since been approved for this purpose. CAR-T cells are cells of the body’s own immune system () that are first harvested from the patient and then modified so that they can specifically recognize and attack cancer cells.

The goal of the CARLOTTA01 study is to investigate the efficacy and safety of a newly developed, as-yet-unapproved CAR-T cell therapy. The drug in question is designated MDC-CAR-BCMA001. The CAR-T cells studied in the CARLOTTA01 trial specifically target , a protein found on the surface of cancer cells that is recognized by the modified CAR-T cells. These are administered as a single infusion; the dosages vary depending on the dose group. A total of four different dosages are being tested. Each patient receives the CAR-T cells once. All study participants receive this therapy; that is, there is only one and no control group. Both the patients and the treating physicians are aware that the treatment is being administered (open-label). This is a so-called Phase 1 study, the goal of which is to determine the dose that is both optimally effective and well-tolerated—with particular attention to side effects and response to therapy. To this end, patients will be monitored for up to 24 months after treatment to assess the therapy’s efficacy and the occurrence of side effects caused by the medication. The key factor is whether or when the disease progresses again during therapy.

Eligible participants include women and men aged 18 and older with treatment-resistant or relapsed multiple myeloma (MM) or diffuse large B-cell lymphoma (DLBCL). Patients must have already received at least two lines of therapy (MM) or, in the case of DLBCL, no further standard therapy must be available. Prerequisites include stable general health and adequate organ function. Patients with central nervous system involvement or those currently participating in other studies are excluded. Ongoing immunosuppressive therapy also results in exclusion.

Facts

  1. Disease: Diffuse large B-cell (DLBCL), (MM).
  2. Cancer characteristics: Recurrent or following prior treatment (at least 2 lines of therapy for MM; no standard treatment options remaining for ).
  3. What the study investigates: Dosage, safety, and tolerability of therapy with -targeted -.
  4. Study objective: To determine the maximum tolerated dose and safety of BCMA-targeted CAR-T cell therapy (determination of the maximum tolerated dose and/or Phase 2 dose)
  5. How long will the study last: approximately 2 years.
  6. Study characteristics: Phase 1 study, single arm (with four dose levels), no control group, open-label.

Trial sites

2 trial sites in Germany are listed.

  • Technische Universität Dresden, NCT/UCC, Early Clinical Trial Unit

    01307 Dresden

    Recruiting
  • Universitätsklinikum Carl Gustav Carus Dresden

    Fetscherstrasse 74, 01307 Dresden

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.